China Oncology Focus: funding combinations

Lee’s spinout China Oncology Focus is banking on in-house combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking venture financing to help it meet its goal of submitting NDAs in China for four oncology programs by YE21.

China Oncology Focus Ltd. (COF) spun out of Lee’s Pharmaceutical Holdings Ltd. last August with China rights to five novel oncology programs

Read the full 766 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE